 Esperion Therapeutics Inc NASDAQ: ESPR reported a first-quarter EPS loss of 3.50, compared to 2.84 a year ago, which missed the analyst consensus estimate of 2.52. The company reported quarterly sales of 7.98 million, which sharply missed the consensus estimate of 26.12 million. 